文献速递泌尿生殖与妇科肿瘤放疗

随机试验中前列腺癌超大分割放疗与中度大分割放疗的晚期毒性比较

Late Toxicity of Prostate Ultrahypofractionated Radiation Therapy Compared With Moderate Hypofractionation in a Randomized Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-11-30

本随机试验纳入80例中高危前列腺癌患者,比较中度大分割(70 Gy/28次)与超大分割(36.25 Gy/5次每周)的晚期毒性、生活质量和泌尿症状评分。两组3级及以上毒性无显著差异(每组仅1例3级事件),2级及以上泌尿和胃肠毒性累积概率及生活质量评分均无显著差异。结论认为每周超大分割放疗耐受性良好,晚期毒性无显著差异。

要点

  • 两组3级及以上毒性无显著差异(P=0.921),每组仅1例3级事件。
  • 5年2级及以上泌尿毒性累积概率:Arm 1为69.0%,Arm 2为87.0%(P=0.132)。
  • 5年2级及以上胃肠毒性累积概率:Arm 1为74.0%,Arm 2为80.0%(P=0.430)。

核心结论

  • 每周超大分割放疗耐受性良好,与中度大分割相比晚期毒性无显著差异。

研究设计与样本

  • 随机试验纳入80例中高危前列腺癌患者,随机分至Arm 1(70 Gy/28次)或Arm 2(36.25 Gy/5次每周)。
  • Arm 1有2例退出,最终Arm 1为36例,Arm 2为42例。

主要发现

  • 基线特征除Arm 2的国际前列腺症状评分更差外无显著差异。
  • 3级及以上毒性无显著差异(P=0.921),每组仅1例3级事件。
  • 2级及以上毒性无显著差异(P=0.280)。
  • 5年2级及以上泌尿毒性累积概率:Arm 1为69.0%,Arm 2为87.0%(P=0.132)。
  • 5年2级及以上胃肠毒性累积概率:Arm 1为74.0%,Arm 2为80.0%(P=0.430)。

关键数值与推荐

  • 晚期毒性采用常见不良事件评价标准及RTOG/SOMA量表评估。
  • 生活质量采用EPIC-26简表评估,泌尿功能采用IPSS评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report late toxicity, quality of life (QOL), and urinary symptom score with prostate cancer radiation therapy in a randomized trial comparing moderate hypofractionation and ultrahypofrationation. METHODS AND MATERIALS: Patients with intermediate and high-risk prostate cancer were randomized to either Arm 1 (70 Gy/28 fractions) or Arm 2 (36.25 Gy/5 weekly fractions). Late toxicity was evaluated using the Common Terminology Criteria for Adverse Events and Radiation Therapy Oncology Group/Subjective, Objective, Management, Analytical scales. QOL was assessed with the Expanded Prostate Inventory Composite-26 Short Form and urinary function with the International Prostate Symptom Score. RESULTS: Eighty participants were randomized. Two from Arm 1 withdrew, leaving 36 patients in Arm 1 and 42 in Arm 2. There were no significant differences in baseline characteristics, except for worse International Prostate Symptom Score in Arm 2. No difference was observed in freedom from grade 3 or worse toxicity between treatments (P = .921), with only a single grade 3 event in each arm. There was no significant difference in freedom from grade 2 or worse toxicity (P = .280). No difference was observed in freedom from grade 2 or worse genitorurinary toxicity, with cumulative probabilities of 69.0% and 87.0% at 5 years for Arms 1 and 2, respectively (0.132). No difference was observed in freedom from grade 2 or worse gastrointestinal toxicity, with cumulative probabilities of 74.0% in Arm 1 and 80.0% in Arm 2 (P = .430). There were no significant differences in Expanded Prostate Inventory Composite-26 Short Form QOL between arms. CONCLUSIONS: Ultrahypofrationation, delivered weekly, is well tolerated with no significant differences in freedom from late toxicity compared with moderate hypofractionation.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Alexander A, Gagne I, Bahl G, et al. Late Toxicity of Prostate Ultrahypofractionated Radiation Therapy Compared With Moderate Hypofractionation in a Randomized Trial. Int J Radiat Oncol Biol Phys. 2023. PMID: 38042451. doi:10.1016/j.ijrobp.2023.11.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。